Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJM300 Phase 3 in Active Ulcerative Colitis
NCT03531892Phase 3Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jun 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of firategrast in ulcerative colitis (UC), sponsored by EA Pharma Co., Ltd.. Started Jun 2018; status: completed.
02
Drugs
firategrast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03531892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531892.